Background Biosimilar versions of widely prescribed drugs, including the tumour‐necrosis
factor antagonist infliximab, are becoming increasingly available. As biosimilars are not …

Background and objectives The 52‐week, randomized, double‐blind, noninferiority,
government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab …

Background: Biological therapy has revolutionized the treatment of inflammatory bowel
disease (IBD). After the expiration of patents for biological innovator products, development …

Abstract Purpose of Review Biosimilars of the reference biologic therapeutics infliximab,
etanercept, adalimumab, and rituximab are entering the market. Clinical and real-world data …

Abstract Background and Aims Biosimilar approval, such as Inflectra™(CT-P13) for treating
ulcerative colitis (UC) and Crohn's disease (CD), has reduced direct drug costs. Though …

Background Though a single nonmedical switch from the originator infliximab (IFX) to a
biosimilar is considered effective and safe for most patients with inflammatory bowel disease …

Aim To review the effectiveness and safety of switching from an originator anti-TNF
(Remicade®) to a biosimilar (CT-P13) in patients with inflammatory bowel disease (IBD) …

Background Infliximab biosimilars have become available for treatment of inflammatory
bowel disease (IBD). However, data showing long‐term safety and effectiveness of …

Background There are few data regarding multiple switching from the originator Infliximab to
its biosimilars. Aim To assess outcomes and patient perspectives in a prospective manner …

Objective To investigate effectiveness of systematic switching treatment from innovator
infliximab to biosimilar infliximab, and its associated factors. Methods In this prospective …